Study of a Potential New Treatment for Patients With Toxic Epidermal Necrolysis (TEN)
| Status: | Archived |
|---|---|
| Conditions: | Skin and Soft Tissue Infections, Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis
To determine whether treatment of patients who have toxic epidermal necrolysis with a drug
called remicaide increases the number of patients who are alive 30 days laters.
This is a pilot (preliminary) study. Patients with a diagnosis of TEN will be asked to
consider participating. The study intervention is a single intravenous dose of remicaide (5
mg/kg). Standard supportive care will be given. The percentage of patients alive at 30
days after treatment with remicaide will be compared to historical controls.
We found this trial at
1
site
Click here to add this to my saved trials
